Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZBIO Zenas BioPharma Inc.

Pre-Mkt 12-19 08:10:04 EST

35.07

-0.74

-2.07%

High37.93	Low34.48	Vol321.88K
Open36.64	D1 Closing35.81	Amplitude9.65%
Mkt Cap1.88B	Tradable Cap738.99M	Total Shares53.68M
T/O11.41M	T/O Rate1.53%	Tradable Shares21.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":35.07,"timestamp":1766091600000,"preClose":35.81,"halted":0,"volume":321876,"delay":0,"floatShares":21071865,"shares":53679166,"eps":-4.527832,"marketStatus":"Pre-Mkt","change":-0.74,"latestTime":"12-19 08:10:04 EST","open":36.64,"high":37.93,"low":34.475,"amount":11409569.69231,"amplitude":0.096481,"askPrice":39.06,"askSize":100,"bidPrice":31.91,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.527832,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766154600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":35.07,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.07,"preClose":35.07,"latestTime":"16:10 EST","volume":2415,"amount":84694.66,"timestamp":1766092204674},"volumeRatio":0.9777746994483066,"impliedVol":0.783,"impliedVolPercentile":0.3429},"requestUrl":"/m/hq/s/ZBIO/tweets","defaultTab":"tweets","newsList":[{"id":"2591244246","title":"Zenas Biopharma Approves 2026 Inducement Plan for New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2591244246","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591244246?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:31","pubTimestamp":1765834281,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. has approved the 2026 Inducement Plan, allowing the company to grant up to 1,000,000 shares of common stock through non-statutory stock options, stock appreciation rights, restricted stock units, restricted stock, and other stock-based awards. The plan includes specific agreements for both standard and global recipients, covering stock options and restricted stock units. These awards are intended for individuals being hired or rehired by the company or its subsidiaries. The full terms of the plan and related agreements are detailed in exhibits attached to the company's latest Form 8-K filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL2QQm96:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2591977645","title":"Zenas BioPharma Reports Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2591977645","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591977645?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:05","pubTimestamp":1765800333,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. announced that its partner, InnoCare Pharma, has achieved the primary endpoint in a Phase 2b clinical study of orelabrutinib, a highly selective CNS-penetrant oral BTK inhibitor, in patients with Systemic Lupus Erythematosus . Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE. InnoCare has also received approval from China's Center for Drug Evaluation  to conduct a Phase 3 registrational clinical trial for orelabrutinib in SLE in China. The results from the Phase 2b study have already been achieved and announced.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL33ZyLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014039.USD","BK0239","ZBIO","IE00BKPKM429.USD","BK4585","688428","SG9999014005.SGD","NDAQ","SG9999014021.USD","BK4139","IE00B64PRP62.GBP","LU2210150020.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2591645971","title":"Zenas Biopharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2B Study of Orelabrutinib, a Btk Inhibitor, for Systemic Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2591645971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591645971?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:05","pubTimestamp":1765800310,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XJ02O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2586107482","title":"Zenas BioPharma, Inc. (ZBIO) Initiated with a Buy at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2586107482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586107482?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:15","pubTimestamp":1764231359,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov initiated coverage with a Buy rating on Zenas BioPharma, Inc. yesterday and set a price target of $55.00. The com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/zenas-biopharma-inc-zbio-initiated-with-a-buy-at-evercore-isi-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/zenas-biopharma-inc-zbio-initiated-with-a-buy-at-evercore-isi-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2586425727","title":"Zenas BioPharma Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2586425727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586425727?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:25","pubTimestamp":1764163500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2025 08:25 ET (13:25 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2585145016","title":"Zenas Biopharma Unveils Pipeline Advances for Autoimmune Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2585145016","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585145016?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:50","pubTimestamp":1763733022,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. has provided an update on its clinical and development pipeline, highlighting progress across multiple late-stage and early-stage immunology and inflammation (I&I) programs. The company reports two late-stage franchise programs targeting four I&I indications, including rheumatology, multiple sclerosis, and dermatology. Obexelimab is advancing through Phase 3 trials for IgG4-related disease, with additional studies in relapsing multiple sclerosis and systemic lupus erythematosus. Orelabrutinib, a BTK inhibitor, has entered Phase 3 trials for primary progressive and secondary progressive multiple sclerosis. The early-stage portfolio includes ZB021, an oral IL-17AA/AF inhibitor, and ZB022, a brain-penetrant TYK2 inhibitor, both expected to begin Phase 1 trials following IND filings in 2026. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL8dwvSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1128205525","title":"Stock Track | Zenas BioPharma Soars 5.60% on Promising Autoimmune Disease Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1128205525","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128205525?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:48","pubTimestamp":1763491699,"startTime":"0","endTime":"0","summary":"Shares of Zenas BioPharma Inc. (ZBIO) surged 5.60% in intraday trading on Tuesday, following the release of a corporate presentation highlighting significant advances in the company's autoimmune...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ZBIO"],"gpt_icon":0},{"id":"1100370043","title":"Stock Track | Zenas BioPharma Soars 5.60% on Pipeline Advances in Autoimmune Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=1100370043","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100370043?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:48","pubTimestamp":1763491696,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) stock surged 5.60% in intraday trading on Tuesday, following the release of a corporate presentation highlighting significant progress in its autoimmune disease therapy...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ZBIO"],"gpt_icon":0},{"id":"2584939378","title":"Zenas Biopharma Unveils Pipeline Advances in Autoimmune Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2584939378","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584939378?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:03","pubTimestamp":1763463839,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. has released a corporate presentation outlining its progress in developing therapies for autoimmune diseases. The company highlights two late-stage franchise programs targeting four immunology and inflammation indications, along with two early-stage programs with best-in-class potential. The pipeline includes candidates such as obexelimab and orelabrutinib, with multiple Phase 2 and Phase 3 clinical trials underway across therapeutic areas including rheumatology, multiple sclerosis, and dermatology. Key data readouts and regulatory milestones are anticipated through 2026, with potential approvals and product launches projected in subsequent years. The executive team is noted for its extensive experience in biopharmaceutical development and commercialization. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL5tdTY1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2583390486","title":"Zenas BioPharma Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583390486","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583390486?lang=en_us&edition=fundamental","pubTime":"2025-11-15 12:17","pubTimestamp":1763180264,"startTime":"0","endTime":"0","summary":"Zenas BioPharma, Inc. ( ($ZBIO) ) has released its Q3 earnings. Here is a breakdown of the information Zenas BioPharma, Inc. presented to its inves...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2583598034","title":"Zenas BioPharma Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598034?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:21","pubTimestamp":1763040060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 08:21 ET (13:21 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2583567296","title":"Zenas BioPharma price target raised to $37 from $34 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2583567296","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583567296?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:36","pubTimestamp":1763037404,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Judah Frommer raised the firm’s price target on Zenas BioPharma (ZBIO) to $37 from $34 and keeps an Overweight rating on the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-raised-to-37-from-34-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-raised-to-37-from-34-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2583480561","title":"Zenas BioPharma’s Promising Autoimmune Platform and Buy Rating Reinforced by Advancements in Obexelimab and Orelabrutinib Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2583480561","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583480561?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:36","pubTimestamp":1763033797,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on ZBIO stock, giving a Buy rating today. Matthew Caufield has given h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/zenas-biopharmas-promising-autoimmune-platform-and-buy-rating-reinforced-by-advancements-in-obexelimab-and-orelabrutinib-trials-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/zenas-biopharmas-promising-autoimmune-platform-and-buy-rating-reinforced-by-advancements-in-obexelimab-and-orelabrutinib-trials-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2583650695","title":"Optimistic Buy Rating for Zenas BioPharma Driven by Promising Clinical Trials and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2583650695","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583650695?lang=en_us&edition=fundamental","pubTime":"2025-11-13 18:35","pubTimestamp":1763030155,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz has maintained their bullish stance on ZBIO stock, giving a Buy rating on October 28. Yigal Nochomovitz has given hi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-zenas-biopharma-driven-by-promising-clinical-trials-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-zenas-biopharma-driven-by-promising-clinical-trials-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2582379829","title":"Zenas BioPharma Q3 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2582379829","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582379829?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:49","pubTimestamp":1762951779,"startTime":"0","endTime":"0","summary":"Zenas BioPharma reported a Q3 net loss Wednesday of $1.22 per diluted share, narrower than a loss of $5.02 a year earlier.Three analysts surveyed by FactSet expected a loss of $0.83.As of Sept. 30, the company said it had $301.6 million in cash, cash equivalents, and investments, which along with $120 million raised from a private placement in October is expected to fund operations and capital expenditures through Q4 of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2582337683","title":"Earnings Flash (ZBIO) Zenas BioPharma Posts Q3 Net Loss $1.22 a Share, vs. FactSet Est of $0.83 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2582337683","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582337683?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:28","pubTimestamp":1762950534,"startTime":"0","endTime":"0","summary":"Earnings Flash (ZBIO) Zenas BioPharma Posts Q3 Net Loss $1.22 a Share, vs. FactSet Est of $0.83 Loss","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2582375913","title":"Zenas BioPharma Q3 EPS $(1.22) Misses $(0.98) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375913","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375913?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:17","pubTimestamp":1762949828,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(0.98) by 24.49 percent. This is a 75.7 percent increase over losses of $(5.02) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48799306/zenas-biopharma-q3-eps-1-22-misses-0-98-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2582375863","title":"Zenas Biopharma Raises $120 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375863","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375863?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:05","pubTimestamp":1762949148,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. announced a private placement financing, raising gross proceeds of $120 million. The private placement saw participation from a syndicate of new and existing investors, including mutual funds and healthcare dedicated funds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL6FwTNl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4585","BK4139","LU2095319765.USD","BK4588","LU2210149790.SGD","ZBIO","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582579375","title":"Zenas Biopharma: Qtrly Net Loss $51.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2582579375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582579375?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:05","pubTimestamp":1762949100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA7QB0Y9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2582375519","title":"Zenas Biopharma: Obexelimab Phase 3 Indigo Trial Topline Results in Immunoglobulin G4-Related Disease (Igg4-Rd) Expected Around Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375519","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375519?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:05","pubTimestamp":1762949100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA7QB0Y9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zenasbio.com","stockEarnings":[{"period":"1week","weight":-0.1278},{"period":"1month","weight":-0.0315},{"period":"3month","weight":0.8516},{"period":"6month","weight":2.8161},{"period":"1year","weight":2.8078},{"period":"ytd","weight":3.2821}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.066193},{"month":2,"riseRate":0.4,"avgChangeRate":-0.014847},{"month":3,"riseRate":0.6,"avgChangeRate":-0.027723},{"month":4,"riseRate":0.5,"avgChangeRate":0.001823},{"month":5,"riseRate":0.75,"avgChangeRate":0.218705},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082782},{"month":7,"riseRate":0.2,"avgChangeRate":-0.126333},{"month":8,"riseRate":0.6,"avgChangeRate":0.033743},{"month":9,"riseRate":0.5,"avgChangeRate":0.044898},{"month":10,"riseRate":0.6,"avgChangeRate":0.128289},{"month":11,"riseRate":0,"avgChangeRate":-0.164546},{"month":12,"riseRate":0.4,"avgChangeRate":0.053544}],"exchange":"NASDAQ","name":"Zenas BioPharma Inc.","nameEN":"Zenas BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zenas BioPharma Inc.,ZBIO,Zenas BioPharma Inc.股票,Zenas BioPharma Inc.股票老虎,Zenas BioPharma Inc.股票老虎国际,Zenas BioPharma Inc.行情,Zenas BioPharma Inc.股票行情,Zenas BioPharma Inc.股价,Zenas BioPharma Inc.股市,Zenas BioPharma Inc.股票价格,Zenas BioPharma Inc.股票交易,Zenas BioPharma Inc.股票购买,Zenas BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction